Global β1 Adrenoceptor Agonists Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global β1 Adrenoceptor Agonists Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Dobutamine
  • 1.4.3 Denopamine
  • 1.4.4 Xamoterol
  • 1.4.5 Others
• 1.5 Market by Application
  • 1.5.1 Global β1 Adrenoceptor Agonists Market Share by Application (2014-2025)
  • 1.5.2 Chronic Heart Failure
  • 1.5.3 Myocardial Infarction
  • 1.5.4 Postoperative Hypotension
  • 1.5.5 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 β1 Adrenoceptor Agonists Market Size
• 2.2 β1 Adrenoceptor Agonists Growth Trends by Regions
  • 2.2.1 β1 Adrenoceptor Agonists Market Size by Regions (2014-2025)
  • 2.2.2 β1 Adrenoceptor Agonists Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 β1 Adrenoceptor Agonists Market Size by by Players
  • 3.1.1 Global β1 Adrenoceptor Agonists Revenue by by Players (2014-2019)
  • 3.1.2 Global β1 Adrenoceptor Agonists Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global β1 Adrenoceptor Agonists Market Concentration Ratio (CR5 and HHI)
• 3.2 β1 Adrenoceptor Agonists Key Players Head office and Area Served
• 3.3 Key Players β1 Adrenoceptor Agonists Product/Solution/Service
• 3.4 Date of Enter into β1 Adrenoceptor Agonists Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global β1 Adrenoceptor Agonists Market Size by Type (2014-2019)
• 4.2 Global β1 Adrenoceptor Agonists Market Size by Application (2014-2019)

5 United States

• 5.1 United States β1 Adrenoceptor Agonists Market Size (2014-2019)
• 5.2 β1 Adrenoceptor Agonists Key Players in United States
• 5.3 United States β1 Adrenoceptor Agonists Market Size by Type
• 5.4 United States β1 Adrenoceptor Agonists Market Size by Application

6 Europe

• 6.1 Europe β1 Adrenoceptor Agonists Market Size (2014-2019)
• 6.2 β1 Adrenoceptor Agonists Key Players in Europe
• 6.3 Europe β1 Adrenoceptor Agonists Market Size by Type
• 6.4 Europe β1 Adrenoceptor Agonists Market Size by Application

7 China

• 7.1 China β1 Adrenoceptor Agonists Market Size (2014-2019)
• 7.2 β1 Adrenoceptor Agonists Key Players in China
• 7.3 China β1 Adrenoceptor Agonists Market Size by Type
• 7.4 China β1 Adrenoceptor Agonists Market Size by Application

8 Japan

• 8.1 Japan β1 Adrenoceptor Agonists Market Size (2014-2019)
• 8.2 β1 Adrenoceptor Agonists Key Players in Japan
• 8.3 Japan β1 Adrenoceptor Agonists Market Size by Type
• 8.4 Japan β1 Adrenoceptor Agonists Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia β1 Adrenoceptor Agonists Market Size (2014-2019)
• 9.2 β1 Adrenoceptor Agonists Key Players in Southeast Asia
• 9.3 Southeast Asia β1 Adrenoceptor Agonists Market Size by Type
• 9.4 Southeast Asia β1 Adrenoceptor Agonists Market Size by Application

10 India

• 10.1 India β1 Adrenoceptor Agonists Market Size (2014-2019)
• 10.2 β1 Adrenoceptor Agonists Key Players in India
• 10.3 India β1 Adrenoceptor Agonists Market Size by Type
• 10.4 India β1 Adrenoceptor Agonists Market Size by Application

11 Central & South America

• 11.1 Central & South America β1 Adrenoceptor Agonists Market Size (2014-2019)
• 11.2 β1 Adrenoceptor Agonists Key Players in Central & South America
• 11.3 Central & South America β1 Adrenoceptor Agonists Market Size by Type
• 11.4 Central & South America β1 Adrenoceptor Agonists Market Size by Application

12 International Players Profiles

• 12.1 Ivax Pharmaceuticals
  • 12.1.1 Ivax Pharmaceuticals Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 β1 Adrenoceptor Agonists Introduction
  • 12.1.4 Ivax Pharmaceuticals Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.1.5 Ivax Pharmaceuticals Recent Development
• 12.2 Physicians Total Care
  • 12.2.1 Physicians Total Care Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 β1 Adrenoceptor Agonists Introduction
  • 12.2.4 Physicians Total Care Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.2.5 Physicians Total Care Recent Development
• 12.3 Baxter Healthcare
  • 12.3.1 Baxter Healthcare Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 β1 Adrenoceptor Agonists Introduction
  • 12.3.4 Baxter Healthcare Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.3.5 Baxter Healthcare Recent Development
• 12.4 Sanofi
  • 12.4.1 Sanofi Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 β1 Adrenoceptor Agonists Introduction
  • 12.4.4 Sanofi Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.4.5 Sanofi Recent Development
• 12.5 Teva Canada
  • 12.5.1 Teva Canada Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 β1 Adrenoceptor Agonists Introduction
  • 12.5.4 Teva Canada Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.5.5 Teva Canada Recent Development
• 12.6 Pfizer
  • 12.6.1 Pfizer Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 β1 Adrenoceptor Agonists Introduction
  • 12.6.4 Pfizer Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.6.5 Pfizer Recent Development
• 12.7 Bedford Laboratories
  • 12.7.1 Bedford Laboratories Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 β1 Adrenoceptor Agonists Introduction
  • 12.7.4 Bedford Laboratories Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.7.5 Bedford Laboratories Recent Development
• 12.8 Novartis
  • 12.8.1 Novartis Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 β1 Adrenoceptor Agonists Introduction
  • 12.8.4 Novartis Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.8.5 Novartis Recent Development
• 12.9 Sterimax
  • 12.9.1 Sterimax Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 β1 Adrenoceptor Agonists Introduction
  • 12.9.4 Sterimax Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.9.5 Sterimax Recent Development
• 12.10 Teligent
  • 12.10.1 Teligent Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 β1 Adrenoceptor Agonists Introduction
  • 12.10.4 Teligent Revenue in β1 Adrenoceptor Agonists Business (2014-2019)
  • 12.10.5 Teligent Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer